Reacting to a patent infringement suit brought earlier this year, an Arizona biotech device manufacturing company filed suit Wednesday against a rival claiming violations of antitrust laws and seeking declaratory judgment of noninfringement.
The battle over generic Topamax continues, even with the dismissal of Mylan Laboratories Inc.’s appeal of a temporary restraining order barring it from bringing a version of Ortho-McNeil Pharmaceutical Inc.’s blockbuster epilepsy drug to market.
Many lawyers face the stressful juggling act of maintaining a successful legal career while raising young children. Amy Goodman felt the circus act was not fair to her children so she decided to stay home—and was still able to have her securities-frosted cake and eat it too.
Abbott Laboratories said Tuesday it will slash the price of Kaletra by more than half in a slew of developing nations, following months of international pressure over the pharmaceutical giant's drug pricing policies in Thailand, which recently broke a patent on the HIV/AIDS treatment.
Despite suffering a defeat in the Schering-Plough case, The Federal Trade Commission intends to continue fighting authorized generics agreements and has vowed to make its crackdown on so-called reverse payments one of the agency’s top priorities in the coming year.
Ilene Knable Gotts loves what she does, and she does quite a lot. At the moment she is a partner in the antitrust department at Wachtell, Lipton, Rosen & Katz and serves as international officer of the American Bar Association’s Section of Antitrust Law.
A federal judge said Tuesday that he will allow Merck & Co. to drop a patent infringement suit it filed to stop Canadian generic drug manufacturer Apotex Inc. from launching a generic equivalent of its osteoporosis drug Fosamax.
Laser eye surgery rivals Synergetics USA Inc. and Iridex Corp. laid down their swords Tuesday, with Synergetics paying $6.5 million to settle the companies’ dueling patent infringement suits.
India’s health minister is calling for Novartis AG to back down from its controversial legal battle to patent Gleevec in the country, reportedly arguing that the Swiss drug maker’s challenge to a key section of India’s patent laws could block global access to affordable drugs.
Hoping to take the air out of Teva Pharmaceuticals USA’s plans for a generic version of its most popular drug, Merck & Co. Inc. has filed a patent lawsuit to keep a competing version of popular asthma and allergy drug Singulair from hitting the market.
AstraZeneca Pharmaceuticals LP has filed suit against the generics arm of Novartis AG in an attempt to stave off competition in the multibillion-dollar market for schizophrenia and bipolar mania treatment Seroquel.
A jury has ordered a physicians group to pay a local doctor $6.3 million after it breached his contract and accused him of abusing alcohol and drugs because he questioned the group’s insurance billing practices, his lawyers said.
Bayer HealthCare AG has filed suit against Teva Pharmaceuticals USA Inc., citing infringement of two patents for its blockbuster antibiotic Avelox.
Johnson & Johnson is asking a federal court to toss a former employee's claim that the pharmaceutical giant unlawfully classifies its sales representatives as exempt from laws requiring overtime pay.
A drug-eluting stent distributed by a Johnson & Johnson Inc. subsidiary does not infringe on a Boston Scientific Corp. patent for a method of administering drugs to treat heart disease, a Delaware federal court has ruled.
The U.S. Patent and Trademark Office will reissue a patent related to Barr Pharmaceuticals Inc.’s oral contraceptive drug Seasonale, according to Barr, marking the latest development in the battle for the multimillion-dollar market for the drug.
The U.S. government, which recently terminated an $877.5 million contract with VaxGen Inc., has agreed to pay the biotechnology company $11 million and not hold it liable for the excess costs of procuring an anthrax vaccine.
Allowing Medicare to negotiate prescription drug prices could save United States taxpayers over $30 billion a year, according to a new report that looks at the costs of a law that prevents the government from seeking better deals on prescription drugs.
Citing an invalid certificate of correction from the U.S. Patent and Trademark Office, a federal appeals court has reversed a lower court ruling that a pharmacy service company willfully infringed a patent for heart-surgery chemical technology.
Johnson & Johnson Inc. has agreed to shell out $11 million to settle an antitrust suit lodged by a medical technology company that accused Johnson & Johnson and three subsidiaries of trying to muscle the plaintiff out of the market for surgical endoscopy products.